No Data
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient With Autoimmune Disease
Keji Pharmaceuticals' universal CD19/CD20 CAR-T product has completed the first administration to a subject with autoimmune disease.
Shanghai, February 28, 2025 /PR Newswire/ -- Kexin Pharmaceuticals (Stock Code: 2171.HK), an innovative CAR-T cell therapy company primarily focused on treating hematologic malignancies and solid tumors, announced that its self-developed universal CAR-T cell therapy candidate KJ-C2219, targeting CD19/CD20, has completed the first administration to a systemic lupus erythematosus subject at the starting dose in a researcher-initiated clinical trial (IIT). KJ-C2219 is developed based on the THANK-u Plus platform.
CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment
Express News | CARsgen Therapeutics - Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln
Trending Industry Today: CARSGEN-B Leads Gains In Pharmaceutical Companies Stocks
Pharmaceutical stocks generally rose, with KCP Pharmaceutical (02171) increasing by 25.29%. Institutions expect that after the first quarter report, the pharmaceutical Sector is likely to see an overall performance reversal in the Industry.
Jinwu Financial News | Pharmaceutical stocks have generally risen, with Keji Pharmaceutical (02171) up 25.29%, INNOCARE (09969) up 14.58%, REMEGEN (09995) up 12.88%, Yiming Anke (01541) up 12.25%, Lepu Biopharma (02157) up 10.67%, YSB (09885) up 6.88%, and Gushengtang (02273) up 6.71%. The Hong Kong stock Pharmaceutical ETF has risen 3.59%, and the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF has risen 4.05%. Ping An Securities stated that on January 17, 2025, the National Healthcare Security Administration will hold a '
Insiders Could Have Profited By Holding Onto CARsgen Therapeutics Holdings Shares Despite 23% Drop
